Strategic collaboration Target pharma and biotech partners with anti-CD47 platforms focusing on solid tumors and multiple myeloma, leveraging AO-176’s tumor-selective binding and immunogenic cell death mechanisms to co-develop or combine therapies with standard regimens.

Clinical pathway leverage Position AO-176’s Phase 1/2 program as a bridge for collaborations with mid-to-large biopharma seeking late-stage immuno-oncology assets to diversify portfolios and accelerate combination trial strategies.

Global research access Propose regional or cross-border trial partnerships leveraging Arch Oncology’s dual footprint in California and Missouri to access diverse patient populations and accelerate recruitment for early-phase studies.

financing and equity Highlight Arch Oncology’s recent successful funding milestones to attract venture co-funding, strategic investments, or milestone-driven partnerships that align with clinical development timelines and risk-sharing models.

Technology and data Offer value through integrating AO-176 with existing preclinical or translational platforms, emphasizing tumor-selective binding and pH-enhanced activity to support companion diagnostic development and biomarker-led trial design.